---
title: "Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275462603.md"
datetime: "2026-02-10T13:02:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275462603.md)
  - [en](https://longbridge.com/en/news/275462603.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275462603.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275462603.md) | [繁體中文](https://longbridge.com/zh-HK/news/275462603.md)


# Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment

Genprex Inc. announced that IP Australia has issued a Notice of Acceptance for its patent application covering the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies for the treatment of cancers. This development provides additional intellectual property protection for the therapeutic combination currently being evaluated in the Acclaim-3 clinical trial. Similar claims have already been granted in the U.S. and Korea, and further patent applications are being pursued in other key international markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA83841) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Genprex, Inc. (GNPX.US)](https://longbridge.com/en/quote/GNPX.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/en/news/281186075.md)
- [MAIA's Phase 2 Trial Shows Eight Lung Cancer Patients Surpassing Two Years Of Survival](https://longbridge.com/en/news/281329946.md)
- [SeaStar Medical Highlights New Positive QUELIMMUNE Data In Pediatric AKI](https://longbridge.com/en/news/281121555.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)
- [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md)